Opus Genetics (NASDAQ: IRD) revenue
Opus Genetics reported revenue of $14.2m for fiscal 2025, 29.1% more than in fiscal 2024 ($11.0m). Since fiscal 2019 its revenue has grown by 373.2%, an average growth of 29.6% a year.
Opus Genetics's best year of the last 7 was fiscal 2022. The biggest drop was in fiscal 2023, −52.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $14.2m | +29.1% | −$38.6m | −271.9% |
| 2024 | $11.0m | −42.3% | −$62.1m | −564.7% |
| 2023 | $19.0m | −52.2% | −$10.6m | −55.5% |
| 2022 | $39.9m | +6,665.7% | $18.2m | 45.7% |
| 2021 | $0.6m | — | −$22.7m | −3,854.8% |
| 2020 | $0.0m | −100.0% | −$20.0m | — |
| 2019 | $3.0m | — | −$4.2m | −139.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Opus Genetics revenue compared with its sector
By revenue for its latest fiscal year, Opus Genetics ranks 360th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Opus Genetics, 29.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 358th | Relay Therapeutics | $15.4m | 53.4% |
| 359th | Lineage Cell Therapeutics | $14.6m | 53.2% |
| 360th | Opus Genetics | $14.2m | 29.1% |
| 361st | Arbutus Biopharma | $14.1m | 128.2% |
| 362nd | Hyperfine | $13.6m | 5.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Opus Genetics
- How much revenue did Opus Genetics make in fiscal 2025?
- Opus Genetics reported revenue of $14.2m for fiscal 2025, compared with $11.0m in fiscal 2024.
- How much has the revenue of Opus Genetics grown?
- Between fiscal 2019 and fiscal 2025 it went from $3.0m to $14.2m: 373.2% more, an average growth of 29.6% a year.
- What was the best year for revenue at Opus Genetics?
- Of its last 7 fiscal years, fiscal 2022, with $39.9m.
- Where does Opus Genetics rank in its sector by revenue?
- It ranks 360th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Opus Genetics come from?
- From the annual report (Form 10-K) that Opus Genetics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Opus Genetics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Opus Genetics: the Opus Genetics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.